REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
